Heparin-induced thrombocytopenia (HIT) has become more prevalent in today’s cardiac setting and has resulted in the need for alternative anticoagulant therapies.
Danaparoid sodium, one alternative to heparin, has been used in six cardiopulmonary bypass procedures in this hospital. This clinical experience has resulted in the progressive refinement of a protocol for the ‘safe’ clinical use of danaparoid sodium.
Although there were six positive outcomes with the use of danaparoid sodium, alternatives must be explored in order to find the optimal anticoagulant for the treatment of HIT.
Wilhelm MJ , Schmid C , Kececioghi Det al.Cardiopulmonary bypass in patients with heparin-induced thrombocytopenia using Orgaran® 10172 . Ann Thorac Surg1996; 61: 920-924 .
Magnani HN , Beijering RJR , Ten Cati JWet al.Orgaran anticoagulation for cardiopulmonary bypass in patients with heparin-induced thrombocytopenia. Reprinted from Roque Pifarre ed. New anticoagulants for the cardiovascular patient. Philadelphia, PA: Hanley & Belfus , 1997: 487-500.
5.
Doherty DC , Ortel TL , DeBruijn Net al.‘Heparin-free’ cardiopulmonary bypass: first reported use of heparinoid (Org. 10172) to provide anticoagulation for cardiopulmonary bypass . Anesthesiology1990; 73: 562-565 .
6.
Ramakrishna R , Manoharan A , Kwan ULet al.Heparin-induced thrombocytopenia: cross-reactivity between standard heparin, low molecular weight heparin, daltepauin (Fragmin) and heparinoid, danaparoid (Orgaran) . Br J Haematol1995; 91: 736-738 .
7.
Gillis S , Merin G , Zahger Det al.Danaparoid for cardiopulmonary bypass in patients with previous heparin-induced thrombocytopenia . Br J Haematol1997; 98: 657-659 .
